NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and Advanced Motion Systems today announce a distribution partnership. Piezo Motion is a developer and leading manufacturer of precision motor technology. Advanced Motion Systems, based in central New York, specializes in industrial automation products and services. Through the partnership, Advanced Motion will expand its market by offering piezoelectric motors to original equipment manufacturers (OEMs) across New York.
Piezo Motion’s multifaceted rotary and linear motors are built with technology that provides a stable, accurate motor that is designed specifically for OEMs that require ultimate speed, size and accuracy.
“Piezo Motion has a unique offering that no one else has, which is the simplicity of the device compared to the competition, and it really got me excited,” explained Tony Overy, president of Advanced Motion Systems. “At the core of our business is motion control. With Piezo Motion we will focus on working with OEMs in the commercial space who need motion control for hand-held devices or medical instruments.”
Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology industries, and industrial electronic and automotive systems, along with an expanding portfolio of products that combine performance with dramatically lower cost over conventional piezo solutions.
“We are pleased with the market’s reaction to our breakthrough technologies,” said Hassan Kotob, chairman and CEO of Brain Scientific. “Our products will allow Advanced Motion to provide innovative and unique solutions to their customers.”
About Piezo Motion
Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today’s global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.
About Brain Scientific
Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultraefficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products or investor relations, please visit brainscientific.com.
About Advanced Motion Systems
For 30 years, Advanced Motion Systems (advancedmotionsys.com) has been providing solutions for a wide spectrum of automation applications. Our clients are machine builders and end users in a wide variety of industry segments, including automotive manufacturing, semiconductor, life sciences, glass fabrication, medical device manufacturing, food and beverage. Our solutions include motion control, machine vision, barcode reading, safety, machine control and robotics. Our team of experienced engineers are passionate about finding the right solutions to your most challenging applications. We are excited to work with Piezo Motion to discover new markets for their innovative leading-edge products.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company’s future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company’s inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company’s raw materials; and the failure to implement the company’s business plans or strategies, including as a result of the closing of the merger with Piezo Motion. Some of these and other factors are identified and described in more detail in the company’s filings with the SEC. The company does not undertake to update these forward-looking statements.